

DAFTAR PUSTAKA

- Adami, H.O., Lambe, M., Persson, I., Ekbom, A., Adami, H.O., Hsieh, C.C., Trichopoulos, D., Ekbom, A., Lambe, M., Leon, D., Janson, P.O., 1994. Parity, age at first childbirth, and risk of ovarian cancer. *Lancet* 344, 1250–1254. [https://doi.org/10.1016/S0140-6736\(94\)90749-8](https://doi.org/10.1016/S0140-6736(94)90749-8)
- Ameye, L., Timmerman, D., Valentin, L., Paladini, D., Zhang, J., van Holsbeke, C., Lissoni, A.A., Savelli, L., Veldman, J., Testa, A.C., Amant, F., van Huffel, S., Bourne, T., 2012. Clinically oriented three-step strategy for assessment of adnexal pathology. *Ultrasound in Obstetrics and Gynecology* 40, 582–591. <https://doi.org/10.1002/UOG.11177>
- Andersen, M.R., Goff, B.A., Lowe, K.A., Scholler, N., Bergan, L., Drescher, C.W., Paley, P., Urban, N., 2010. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. *Gynecol Oncol* 116, 378–383. <https://doi.org/10.1016/J.YGYNO.2009.10.087>
- Badora-Rybicka, A., Nowara, E., Starzyczny-Słota, D., 2016. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. *ESMO Open* 1. <https://doi.org/10.1136/ESMOOPEN-2016-000039>
- Babic, A., Cramer, D.W., Kelemen, L.E., Köbel, M., Steed, H., Webb, P.M., Johnatty, S.E., deFazio, A., Lambrechts, D., Goodman, M.T., Heitz, F., Matsuo, K., Hosono, S., Karlan, B.Y., Jensen, A., Kjær, S.K., Goode, E.L., Pejovic, T., Moffitt, M., Høgdall, E., Høgdall, C., McNeish, I., Terry, K.L., 2017. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes and Control* 28, 459–468. <https://doi.org/10.1007/s10552-016-0841-3>
- Barton, B. and Peat, J., 2014. *Medical Statistics. A Guide to SPSS, Data Analysis and Critical Appraisal*. Second edition. John Wiley & Sons Ltd. www.wiley.com/wiley-blackwell
- Berek, J.S., Crum, C., Friedlander, M., 2015. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* 131 Suppl 2, S111–S122. <https://doi.org/10.1016/J.IJGO.2015.06.007>
- Berek, J.S., Renz, M., Kehoe, S., Kumar, L., Friedlander, M., 2021. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynaecol Obstet* 155 Suppl 1, 61–85. <https://doi.org/10.1002/IJGO.13878>

- Borges, T.C., Gomes, T.L., Pichard, C., Laviano, A., Pimentel, G.D., 2021. High neutrophil to lymphocytes ratio is associated with sarcopenia risk in hospitalized cancer patients. *Clin Nutr* 40, 202–206. <https://doi.org/10.1016/J.CLNU.2020.05.005>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68, 394–424. <https://doi.org/10.3322/CAAC.21492>
- Brewster, D.H., 2001. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. *BMJ* 322, 830–831. <https://doi.org/10.1136/bmj.322.7290.830>
- Cannistra, S.A., 2004. Cancer of the ovary. *N Engl J Med* 351, 2519–2529. <https://doi.org/10.1056/NEJMRA041842>
- Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S.A., Akbari, M.R., 2020. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)* 12, 1–29. <https://doi.org/10.3390/CANCERS12123730>
- Chen, S., Zhang, L., Yan, G., Cheng, S., Fathy, A.H., Yan, N., Zhao, Y., 2017. Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis. *Biomed Res Int* 2017. <https://doi.org/10.1155/2017/7943467>
- Coburn, S.B., Bray, F., Sherman, M.E., Trabert, B., 2017. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. *Int J Cancer* 140, 2451–2460. <https://doi.org/10.1002/IJC.30676>
- Colomiere, M., Ward, A.C., Riley, C., Trenerry, M.K., Cameron-Smith, D., Findlay, J., Ackland, L., Ahmed, N., 2009. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. *Br J Cancer* 100, 134–44. <https://doi.org/10.1038/sj.bjc.6604794>
- Cristea, M., Han, E., Salmon, L., Morgan, R.J., 2010. Practical considerations in ovarian cancer chemotherapy. *Ther Adv Med Oncol* 2, 175–187. <https://doi.org/10.1177/1758834010361333>
- Dahlan, S., 2016. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan Edisi 4. *Epidemiologi Indonesia*

- Delort, L., Kwiatkowski, F., Chalabi, N., Satih, S., Bignon, Y.J., Bernard-Gallon, D.J., 2009. Central adiposity as a major risk factor of ovarian cancer. *Anticancer Res* 29, 5229–5234.
- Doubeni, C.A., Doubeni, A.R.B., Myers, A.E., 2016. Diagnosis and Management of Ovarian Cancer. *Am Fam Physician* 93, 937–944.
- Eo, W.K., Kim, K.H., Park, E.J., Kim, H.Y., Kim, H. bae, Koh, S.B., Namkung, J., 2018. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. *J Cancer* 9, 1165–1172. <https://doi.org/10.7150/JCA.23606>
- Ferrarow, S., Braga, F., Lanzoni, M., Boracchi, P., Biganzoli, E.M., Panteghini, M., 2013. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. *J Clin Pathol* 66, 273–281. <https://doi.org/10.1136/JCLINPATH-2012-201031>
- Field, A., *Discovering Statistics Using SPSS*. SAGE Publications. ISM (London, England). 2009
- Ghozali, I., 2011. *Aplikasi Analisis Multivariate dengan Program IBM SPSS 19*. Edisi 5. Badan Penerbit Universitas Diponegoro
- Grivennikov, S.I., Greten, F.R., Karin, M., 2010. Immunity, inflammation, and cancer. *Cell* 140, 883–899. <https://doi.org/10.1016/J.CELL.2010.01.025>
- Huang, Q.T., Zhou, L., Zeng, W.J., Ma, Q.Q., Wang, W., Zhong, M., Yu, Y.H., 2017. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. *Cell Physiol Biochem* 41, 2411–2418. <https://doi.org/10.1159/000475911>
- Indonesia KKR, 2019. *InfoDATIN (Pusat Data dan Informasi Kementerian Kesehatan RI)*, Jakarta, Kementerian Kesehatan RI.
- Jordan, S.J., Siskind, V., C Green, A., Whiteman, D.C., Webb, P.M., 2010. Breastfeeding and risk of epithelial ovarian cancer. *Cancer Causes Control* 21, 109–116. <https://doi.org/10.1007/S10552-009-9440-X>
- Kaku, T., Ogawa, S., Kawano, Y., Ohishi, Y., Kobayashi, H., Hirakawa, T., Nakano, H., 2003. Histological classification of ovarian cancer. *Medical Electron Microscopy* 2003 36:1 36, 9–17. <https://doi.org/10.1007/S007950300002>

- Kim, Y.J., Lee, I., Chung, Y.S., Nam, E.J., Kim, S., Kim, S.W., Kim, Y.T., Lee, J.Y., 2018. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. *Obstet Gynecol Sci* 61, 227–234. <https://doi.org/10.5468/ogs.2018.61.2.227>
- Kolaczowska, E., Kubes, P., 2013. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol* 13, 159–175. <https://doi.org/10.1038/NRI3399>
- Kurman, R.J., Shih, I.M., 2016. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. *Am J Pathol* 186, 733–747. <https://doi.org/10.1016/J.AJPATH.2015.11.011>
- Li, L., Tian, J., Zhang, L., Liu, L., Sheng, C., Huang, Y., Zheng, H., Song, F., Chen, K., 2021. Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. *J Cancer* 12, 2687–2693. <https://doi.org/10.7150/JCA.51642>
- Macciò, A., Madeddu, C., 2012a. Inflammation and ovarian cancer. *Cytokine* 58, 133–47. <https://doi.org/10.1016/j.cyto.2012.01.015>
- Macciò, A., Madeddu, C., 2012b. Inflammation and ovarian cancer. *Cytokine* 58, 133–147. <https://doi.org/10.1016/J.CYTO.2012.01.015>
- Mancari, R., Cutillo, G., Bruno, V., Vincenzoni, C., Mancini, E., Baiocco, E., Bruni, S., Vocaturo, G., Chiofalo, B., Vizza, E., 2020. Development of new medical treatment for epithelial ovarian cancer recurrence. *Gland Surg* 9, 1149–1163. <https://doi.org/10.21037/GS-20-413>
- McCluggage, W.G., 2011. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. *Pathology* 43, 420–432. <https://doi.org/10.1097/PAT.0B013E328348A6E7>
- Miao, Y., Yan, Q., Li, S., Li, B., Feng, Y., 2016. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. *Cancer Biomark* 17, 33–40. <https://doi.org/10.3233/CBM-160614>
- Modugno, F., Edwards, R.P., 2012. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. *Int J Gynecol Cancer* 22. <https://doi.org/10.1097/IGC.0B013E31826BD1F2>

- Mogensen, J.B., Kjær, S.K., Mellemkjær, L., Jensen, A., 2016. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. *Gynecol Oncol* 143, 87–92. <https://doi.org/10.1016/J.YGYNO.2016.07.095>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., Salehiniya, H., 2019. <p>Ovarian cancer in the world: epidemiology and risk factors</p>. *Int J Womens Health* Volume 11, 287–299. <https://doi.org/10.2147/IJWH.S197604>
- Moorman, P.G., Schildkraut, J.M., Calingaert, B., Halabi, S., Vine, M.F., Berchuck, A., 2002. Ovulation and ovarian cancer: A comparison of two methods for calculating lifetime ovulatory cycles (United States). *Cancer Causes and Control* 13, 807–811. <https://doi.org/10.1023/A:1020678100977>
- Mori, M., Harabuchi, I., Miyake, H., Casagrande, J.T., Henderson, B.E., Ross, R.K., 1988. Reproductive, Genetic, and Dietary Risk Factors for Ovarian Cancer. *Am J Epidemiol* 128, 771–777. <https://doi.org/10.1093/oxfordjournals.aje.a115030>
- Nakamura, K., Nagasaka, T., Nishida, T., Haruma, T., Ogawa, C., Kusumoto, T., Seki, N., Hiramatsu, Y., 2016. Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. *Oncol Lett* 11, 3975–3981. <https://doi.org/10.3892/ol.2016.4513>
- Okunade, K.S., Adetuyi, I.E., Adenekan, M., Ohazurike, E., Anorlu, R.I., 2020. Risk predictors of early recurrence in women with epithelial ovarian cancer in lagos, nigeria. *Pan African Medical Journal* 36, 1–9. <https://doi.org/10.11604/pamj.2020.36.272.17827>
- Pavone, M.E., Lyttle, B.M., 2015. Endometriosis and ovarian cancer: links, risks, and challenges faced. *Int J Womens Health* 7, 663–672. <https://doi.org/10.2147/IJWH.S66824>
- Piatek, S., Panek, G., Lewandowski, Z., Bidzinski, M., Piatek, D., Kosinski, P., Wielgos, M., 2020. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. *J Ovarian Res* 13. <https://doi.org/10.1186/s13048-020-00681-0>
- Querleu, D., Planchamp, F., Chiva, L., Fotopoulou, C., Barton, D., Cibula, D., Aletti, G., Carinelli, S., Creutzberg, C., Davidson, B., Harter, P., Lundvall, L., Marth, C., Morice, P., Rafii, A., Ray-Coquard, I., Rockall, A., Sessa, C., van der Zee, A., Vergote, I., DuBois, A., 2017. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.

International Journal of Gynecological Cancer 27, 1534–1542.
<https://doi.org/10.1097/IGC.0000000000001041>

Reid, F., Bhatla, N., Oza, A.M., Blank, S. v., Cohen, R., Adams, T., Benites, A., Gardiner, Di., Gregory, S., Suzuki, M., Jones, A., 2021. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. *Int J Gynecol Cancer* 31, 238–244. <https://doi.org/10.1136/IJGC-2019-000983>

Rosen, D.G., 2009. Ovarian cancer: pathology, biology, and disease models. *Frontiers in Bioscience Volume*, 2089. <https://doi.org/10.2741/3364>

Salazar-Martínez, E., Lazcano-Ponce, E., Lira-Lira, G.G., Ríos, P.M.E. los, Salmerón-Castro, J., Hernández-Ávila, M., 1999. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. undefined.

Sastroasmoro, S., Ismael, S., 2010. *Dasar-Dasar Metodologi Penelitian Klinis Edisi Ketiga*

Savant, S.S., Sriramkumar, S., O'Hagan, H.M., 2018. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. *Cancers (Basel)* 10. <https://doi.org/10.3390/cancers10080251>

Sumanasekera, W., Beckmann, T., Fuller, L., Castle, M., Huff, M., 2018. Epidemiology of Ovarian Cancer: Risk Factors and Prevention. *Biomed J Sci Tech Res* 11, 001–013. <https://doi.org/10.26717/BJSTR.2018.11.002076>

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 71, 209–249. <https://doi.org/10.3322/caac.21660>

Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., Gaudet, M.M., Jemal, A., Siegel, R.L., 2018. Ovarian cancer statistics, 2018. *CA Cancer J Clin* 68, 284–296. <https://doi.org/10.3322/CAAC.21456>

Ushijima, K., 2010. Treatment for recurrent ovarian cancer-at first relapse. *J Oncol* 2010. <https://doi.org/10.1155/2010/497429>

van der Zee, A.G., de Cuyper, E.M., Limburg, P.C., de Bruijn, H.W., Hollema, H., Bijzet, J., Krans, M., de Vries, E.G., 1995. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors

correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75, 1004–9. [https://doi.org/10.1002/1097-0142\(19950215\)75:4<1004::aid-cnrcr2820750416>3.0.co;2-g](https://doi.org/10.1002/1097-0142(19950215)75:4<1004::aid-cnrcr2820750416>3.0.co;2-g)

Wang, N., Li, C., Yang, Y., Guan, Y., Wang, F., Wang, Y., Zhao, W., 2021. The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain. World Neurosurg 149, 502–510. <https://doi.org/10.1016/j.wneu.2020.11.117>

Winarno, G.N.A., Pasaribu, M., Susanto, H., Nisa, A.S., Harsono, A.B., Yuseran, H., Suardi, D., Trianasari, N., 2021. The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer. Asian Pac J Cancer Prev 22, 1561–1566. <https://doi.org/10.31557/APJCP.2021.22.5.1561>

Wohlmuth, C., Djedovic, V., Kjaer, S.K., Jensen, A., Glasspool, R., Roxburgh, P., Defazio, A., Johnatty, S.E., Webb, P.M., Modugno, F., Lambrechts, D., Schildkraut, J.M., Berchuck, A., Thomsen, L.C.V., Bjorge, L., Høgdall, E., Høgdall, C.K., Goode, E.L., Winham, S.J., Matsuo, K., Karlan, B.Y., Lester, J., Goodman, M.T., Thompson, P.J., Pejovic, T., Riggan, M.J., Lajkosz, K., Tone, A., May, T., 2022. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. Cancers (Basel) 14. <https://doi.org/10.3390/cancers14081954>

Zhang, C. long, Jiang, X. chen, Li, Y., Pan, X., Gao, M. qi, Chen, Y., Pang, B., 2023. Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR. J Ovarian Res. <https://doi.org/10.1186/s13048-023-01116-2>

Zhang, H., Huo, Q., Huang, L., Cheng, Y., Liu, Y., Bao, H., 2019. Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration. Biomed Res Int 2019. <https://doi.org/10.1155/2019/8107906>

Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., Li, Y., 2021. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6. <https://doi.org/10.1038/S41392-021-00658-5>